Novavax, Inc. (NVAX)
Pre-Market:
| Previous Close | 3.9700 |
| Open | 3.9900 |
| Bid | 4.0300 x 1000 |
| Ask | 4.1300 x 600 |
| Day's Range | 3.9100 - 4.1300 |
| 52 Week Range | 3.5300 - 11.3600 |
| Volume | |
| Avg. Volume | 7,326,375 |
| Market Cap | 569.609M |
| Beta (5Y Monthly) | 1.60 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
- Insider Monkey
12 Most Shorted Stocks in 2024
In this article, we will take a detailed look at the 12 Most Shorted Stocks in 2024. For a quick overview of such stocks, read our article 5 Most Shorted Stocks in 2024. Short-sellers may be annoying for corporations (and Redditors?), but investors usually find themselves thanking these companies for doing the often back-breaking and excruciating research that […]
- Reuters
UPDATE 4-Novavax investor Shah Capital pushes for board shakeup
Novavax shareholder Shah Capital is pushing the vaccine maker to add two of its nominees to the board to help tackle "underperformance" at the company and improve its share price. The hedge fund nominated Suresh Katta, founder and CEO of biotech firm Saama, and Venkat Peri, CEO of Quantiva Health, to Novavax's eight-member board, saying the duo had the experience in setting the company's strategic direction.
